145888-79-5

145888-79-5 structure

Name: PTP1B-IN-9
Chemical Name: (3E,5E)-3,5-Bis(3,4-Dichlorobenzylidene)Piperidin-4-One
CAS Number: 145888-79-5
Molecular Formula: C₁₉H₁₃Cl₄NO
Molecular Weight: 413.12500
Catalog: Signaling Pathways Metabolic Enzyme/Protease Proteasome
Create Date: 2018-01-03 02:50:08
Modify Date: 2025-08-27 14:45:26
PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity[1].

Name	(3E,5E)-3,5-Bis(3,4-Dichlorobenzylidene)Piperidin-4-One

Description	PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Proteasome
In Vitro	PTP1B-IN-9 (0-30 µM; 48 hours) treatment produces a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively[1]. PTP1B-IN-9 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 µM[1]. Cell Viability Assay[1] Cell Line: Keratinocytes, SiHa, CaSki and ME180 cells Concentration: 5, 10, 15, 20, 25, 30 µM Incubation Time: 48 hours Result: Produced a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively with minimal effects on the viability of primary human keratinocytes and with IC50 similar to the obtained with HeLa cells.
References	[1]. Anchoori RK, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.PLoS One. 2011;6(8):e23888.